{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116252","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.269383+00:00","generated_at":"2026-06-22T00:32:11.256932+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ANI Pharma Q3 2022: Record revenue $83.8M (+61% YoY); GAAP loss $(9.0M); adj. EPS $0.64; Cortrophin $12.6M","bullets":["Record net revenues of $83.8M, up 61% YoY from $52.1M.","GAAP net loss $(9.0M) and diluted loss per share $(0.55), compared to loss $(4.4M) and $(0.37) in Q3 2021.","Adjusted non-GAAP EBITDA $19.6M (nearly double Q2 2022) and adjusted diluted EPS $0.64, down from $1.01 in Q3 2021.","Cortrophin net sales $12.6M; cumulative patient cases 765+; reiterated full-year Cortrophin revenue guidance $40-45M; full-company guidance also reaffirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116252","json":"https://secwatch.observer/filing/0001104659-22-116252.json","markdown":"https://secwatch.observer/filing/0001104659-22-116252.md","text":"https://secwatch.observer/filing/0001104659-22-116252.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000110465922116252/0001104659-22-116252-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000110465922116252/tm2230118d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:32:11.256932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d3539447eacb129ce3d1da036adf69c5c9526947","claim":"ANI PHARMACEUTICALS INC reported three and nine months ended September 30, 2022 results: revenue $83.8 million, net income $(9.0) million, EPS $(0.55). Guidance reaffirmed.","evidence_excerpt":"ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues Third Quarter 2022 Results: -- Net revenues of $83.8 million, net loss available to common shareholders of $(9.0) million and diluted GAAP loss per share of $(0.55)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000110465922116252/0001104659-22-116252-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2022"},{"label":"Revenue","value":"$83.8 million"},{"label":"Net income","value":"$(9.0) million"},{"label":"EPS","value":"$(0.55)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}